| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18435 R78127 |
Lee (Controls exposed to TCAs), 2025 | Preterm birth (infant born at gestational age <37 weeks) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) |
1.05 [0.46;2.39] C excluded (control group) |
7/71 58/613 | 65 | 71 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18414 R77822 |
Lee (Controls unexposed, general pop), 2025 | Preterm birth (infant born at gestational age <37 weeks) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 1.03 [0.47;2.26] | 7/71 28,543/463,440 | 28,550 | 71 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18219 R76441 |
Martin, 2024 | Preterm delivery (delivery at <259 days (37 weeks’)) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 1.16 [1.08;1.24] | 1,015/15,406 119,950/2,408,707 | 120,965 | 15,406 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13122 R50028 |
Marks (Controls exposed to Bupropion), 2021 | Preterm Birth | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 0.97 [0.68;1.38] C | 85/581 61/406 | 146 | 581 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7520 R22543 |
Ozturk, 2016 | Preterm Births (<37 weeks) | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified | 1.03 [0.12;8.50] C | 1/30 8/246 | 9 | 30 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6190 R16314 |
Klieger-Grossmann, 2012 | Premature birth (< 37 weeks's gestation) | during pregnancy (anytime or not specified) | prospective cohort | unexposed (general population or NOS) | Adjustment: No Matched Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) | 2.51 [1.10;5.71] C | 19/172 9/191 | 28 | 172 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 1.15 [1.00;1.33] | 149,698 | 16,260 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, general pop; 2: Controls exposed to Bupropion;
Asymetry test p-value = 0.8199 (by Egger's regression)
slope=0.1383 (0.0523); intercept=0.1692 (0.6813); t=0.2483; p=0.8199
excluded 18435